Micelle-Enhanced conventional and synchronous spectrofluorimetric methods for the simultaneous determination of lesinurad and febuxostat: Application to human plasma.

A simple synchronous spectrofluorimetric method was developed for simultaneous determination of lesinurad and febuxostat. The investigated drugs were measured at 294 and 329 nm, respectively in the presence of each other without interference at Δλ of 50 nm (Method I). The different experimental parameters affecting the fluorescence intensities were carefully studied and optimized. The maximum synchronous fluorescence intensities were obtained at pH 6.5 using borate buffer and distilled water was used as a diluting solvent. Excellent linearity ranges were obtained using 20.0-500.0 ng mL-1 and 1.0-80.0 ng mL-1 for lesinurad and febuxostat, respectively. The method exhibited high sensitivity with detection limits down to 4.0 ng mL-1 and 0.01 ng mL-1 and quantitation limits down to 12.12 ng mL-1 and 0.02 ng mL-1, respectively. Recovery percentages ranged from 97.68 to 103.37% were obtained upon spiking of human plasma samples, indicating high bioanalytical applicability. Concerning Method II, methanolic solution of lesinurad was measured spectroflourimetrically with λexcitation at 290 nm and λemission at 341 nm with high sensitivity using borate buffer of pH 6.5 and methanol as a diluting solvent. A considerable enhancement of the fluorescence intensity was achieved by using 1.0% w/v cetremide as a micellar system. The method was rectilinear over the concentration range of 3.0-80.0 ng mL-1 with detection and quantitation limits down to 0.47 and 1.42 ng mL-1, respectively. The developed method was efficiently applied for the estimation of the cited drug in spiked human plasma with high recovery percentages (98.58-101.64%). The methods were validated according to the ICH guidelines and further applied to commercial tablets with good results.

Development of a micelle-enhanced high-throughput fluorometric method for determination of niclosamide using a microplate reader.

The present paper describes the development and validation of a simple and sensitive micelle-enhanced high-throughput fluorometric method for the determination of niclosamide (NIC) in 96-microwell plates. The proposed method is based on the reduction of the nitro group of niclosamide to an amino group using Zn/HCl to give a highly fluorescent derivative that was developed simultaneously and measured at λem 444 nm after excitation at λex 275 nm. Tween-80 and carboxymethylcellulose (CMC) have been used as fluorescence enhancers and greatly enhanced the fluorescence by factors of 100-150%. The different experimental conditions affecting the fluorescence reaction were carefully investigated and optimized. The proposed method showed good linearity (r2 ≥ 0.9997) over the concentration ranges of 1-5 and 0.5-5 µg/ml with lower detection limits of 0.01 and 0.008 µg/ml and lower quantification limits of 0.04 and 0.03 µg/ml on using Tween-80 and or CMC, respectively. The developed high-throughput method was successfully applied for the determination of niclosamide in both tablets and spiked plasma. The capability of the method for measuring microvolume samples made it convenient for handling a very large number of samples simultaneously. In addition, it is considered an environmentally friendly method with lower consumption of chemicals and solvents.

Selective and sensitive spectrofluorimetric quantification of velpatasvir in presence of sofosbuvir. Application to their co-formulated tablet.

A new sensitive, rapid and simple spectrofluorimetric method was utilized for the assessment of velpatasvir (VPS) in its bulk form as well as in its combined tablet with sofosbovir (SFV). The technique relies on measuring the native fluorescence of VPS in methanol at 385 nm and 400 nm after excitation at 295 nm. The fluorescence-concentration plots were rectilinear through the range of 2.0-20.0 ng mL-1 at both emission maxima with lower detection limits of 0.146 ng mL-1 and 0.378 ng mL-1, and lower quantification limits of 0.444 ng mL-1 and 1.147 ng mL-1 at 385 nm and 400 nm, respectively. The proposed method was appropriately used for the analysis of VPS in its commercial tablet formulation and the results were in good agreement with those achieved with the applied comparison method.

Stacking-cyclodextrin-microchip electrokinetic chromatographic determination of gabapentinoid drugs in pharmaceutical and biological matrices.

A facile, rapid, and highly sensitive microchip-based electrokinetic chromatographic method was developed for the simultaneous analysis of two gabapentinoid drugs, gabapentin (GPN) and pregabalin (PGN). Both drugs were first reacted with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) via nucleophilic substitution reactions to yield highly fluorescent products with λex/em 470/540nm. Analyses of both fluorescently labeled compounds were achieved within 200s in a poly(methyl methacrylate) (PMMA) microchip with a 30mm separation channel. Optimum separation was achieved using a borate buffer (pH 9.0) solution containing methylcellulose and ß-cyclodextrin (ß-CD) as buffer additives. Methylcellulose acted as a dynamic coating to prevent adsorption of the studied compounds on the inner surfaces of the microchannels, while ß-CD acted as a pseudo-stationary phase to improve the separation efficiency between the labeled drugs with high resolution (Rs>7). The fluorescence intensities of the labeled drugs were measured using a light emitting diode-induced fluorescence detector at 540nm after excitation at 470nm. The sensitivity of the method was enhanced 14- and 17-fold for PGN and GPN, respectively by field-amplified stacking relative to traditional pinched injection so that it could quantify 10ngmL-1 for both analytes, with a detection limit lower than 3ngmL-1. The developed method was efficiently applied to analyze PGN and GPN in their pharmaceutical dosage forms and in biological fluids. The extraction recoveries of the studied drugs from plasma and urine samples were more than 89% with%RSD values lower than 6.2.

Derivative spectrophotometric and liquid chromatographic methods for the simultaneous determination of metoclopramide hydrochloride and aspirin in pharmaceuticals.

Two simple analytical methods were developed and validated for the analysis of a binary mixture of metoclopramide (MET) and aspirin (ASP). The first method depends on measuring the first derivative amplitudes at 257 nm for MET and at 310 nm for ASP, respectively. The calibration graphs were linear in the range of 0.25-20.0 µg/mL for MET and 10.0-200.0 µg/mL for ASP. For the second method, good chromatographic separation was achieved using Promosil C18 column (250 × 4.6 mm i.d., 5 µm particle size). Mobile phase consisting of methanol and 0.02 M phosphate buffer in the ratio of 60:40 (v/v) at pH 4.0 was pumped at a flow rate of 1 mL/min with UV detection at 260 nm. Indapamide was used as an internal standard. The method showed good linearity over the concentration ranges of 0.20-10.0 and 10.0-200.0 µg/mL with limits of detection of 0.06, 1.81 µg/mL and limits of quantification of 0.17, 5.46 µg/mL for MET and ASP, respectively. The results of the proposed methods were statistically compared with those obtained by the official United States Pharmacopeia method revealing non-significant differences in the performance of the methods regarding accuracy and precision. The suggested methods were successfully applied for the simultaneous analysis of the studied drugs in their co-formulated tablets as well as in their single dosage forms.

Micellar liquid chromatographic method for the simultaneous determination of Levofloxacin and Ambroxol in combined tablets: Application to biological fluids.

BACKGROUND: Levofloxacin hemihydrate (LEV) and ambroxol HCl (AMB) are available for the treatment of upper and lower respiratory tract infections. A survey of the literature reveals that two reversed phase HPLC methods were e reported for the simultaneous determination of LEV and AMB in pharmaceutical preparations. However the reported methods suffers from the low sensitivity, no application of the method in the combined tablets and no application to biological fluids. Also the toxic effects of the used solvents which are harmful to human beings. For this reason, our target was to develop a simple sensitive, less hazardous micellar HPLC method for the simultaneous determination of LEV and AMB in their combined dosage forms and plasma. RESULTS: The method showed good linearity over the ranges of 1-44 µg/mL and 1-20 µg/mL with limits of detection 0.26 and 0.07 µg/mL and limits of quantification 0.80 and 0.20 µg/mL for LEV and AMB, respectively. The method was further extended to the determination of LEV in spiked human plasma with mean percentage recoveries of 100.10% ± 1.14 as well as determination of LEV in real human plasma without prior extraction. Statistical evaluation of the data was performed according to ICH Guidelines. CONCLUSION: The suggested method was successfully applied for the simultaneous analysis of the studied drugs in their co-formulated tablets and human plasma. The mean percentage recoveries in combined tablets were 100.20 ± 1.64 and 100.72 ± 1.11 for LEV and AMB, respectively and 100.10 ± 1.14 for LEV in spiked human plasma. Statistical comparison of the results with those of the comparison method revealed good agreement and proved that there were no significant difference in the accuracy and precision between the two methods respectively.

Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma.

BACKGROUND: Rosiglitazone (ROZ) and glimepiride (GLM) are antidiabetic agents used in the treatment of type 2 diabetes mellitus. A survey of the literature reveals that only one spectrophotometric method has been reported for the simultaneous determination of ROS and GLM in pharmaceutical preparations. However the reported method suffers from the low sensitivity, for this reason, our target was to develop a simple sensitive HPLC method for the simultaneous determination of ROZ and GLM in their combined dosage forms and plasma. RESULTS: A simple reversed phase high performance liquid chromatographic (RP-HPLC) method was developed and validated for the simultaneous determination of Rosiglitazone (ROS) and Glimepiride (GLM) in combined dosage forms and human plasma. The separation was achieved using a 150 mm × 4.6 mm i.d., 5 µm particle size Symmetry® C18 column. Mobile phase containing a mixture of acetonitrile and 0.02 M phosphate buffer of pH 5 (60: 40, V/V) was pumped at a flow rate of 1 mL/min. UV detection was performed at 235 nm using nicardipine as an internal standard. The method was validated for accuracy, precision, specificity, linearity, and sensitivity. The developed and validated method was successfully used for quantitative analysis of Avandaryl™ tablets. The chromatographic analysis time was approximately 7 min per sample with complete resolution of ROS (tR = 3.7 min.), GLM (tR = 4.66 min.), and nicardipine (tR, 6.37 min). Validation studieswas performed according to ICH Guidelines revealed that the proposed method is specific, rapid, reliable and reproducible. The calibration plots were linear over the concentration ranges 0.10-25 µg/mL and 0.125-12.5 µg/mL with LOD of 0.04 µg/mL for both compounds and limits of quantification 0.13 and 0.11 µg/mL for ROS and GLM respectively. CONCLUSION: The suggested method was successfully applied for the simultaneous analysis of the studied drugs in their co-formulated tablets and human plasma. The mean percentage recoveries in Avandaryl™ tablets were 100.88 ± 1.14 and 100.31 ± 1.93 for ROS and GLM respectively. Statistical comparison of the results with those of the reference method revealed good agreement and proved that there were no significant difference in the accuracy and precision between the two methods respectively. The interference likely to be introduced from some co-administered drugs such as glibenclamide, gliclazide, metformine, pioglitazone and nateglinide was investigated.

Spectrophotometric determination of tizanidine and orphenadrine via ion pair complex formation using eosin Y.

A simple, sensitive and rapid spectrophotometric method was developed and validated for the determination of two skeletal muscle relaxants namely, tizanidine hydrochloride (I) and orphenadrine citrate (II) in pharmaceutical formulations. The proposed method is based on the formation of a binary complex between the studied drugs and eosin Y in aqueous buffered medium (pH 3.5). Under the optimum conditions, the binary complex showed absorption maxima at 545 nm for tizanidine and 542 nm for orphenadrine. The calibration plots were rectilinear over concentration range of 0.5-8 µg/mL and 1-12 µg/mL with limits of detection of 0.1 µg/mL and 0.3 µg/mL for tizanidine and orphenadrine respectively. The different experimental parameters affecting the development and stability of the complex were studied and optimized. The method was successfully applied for determination of the studied drugs in their dosage forms; and to the content uniformity test of tizanidine in tablets.

Validated spectrofluorimetric method for the determination of lamotrigine in tablets and human plasma through derivatization with o-phthalaldehyde.

A sensitive, simple and selective spectrofluorimetric method was developed for the determination of Lamotrigine (LMT) in pharmaceutical formulations and biological fluids. The method is based on reaction of LMT with o-phthalaldehyde in presence of 2-mercaptoethanol in borate buffer of pH 9.8 to yield a highly fluorescent derivative that is measured at 448 nm after excitation at 337 nm. The different experimental parameters affecting the development and stability of the reaction product were carefully studied and optimized. The fluorescence-concentration plot was rectilinear over the range of 0.1-1.0 microg ml(-1) with lower limit of detection (LOD) 0.02 microg ml(-1) and limit of quantification (LOQ) 0.06 microg ml(-1) respectively. The proposed method was successfully applied to the the analysis of commercial tablets. Statistical comparison of the results obtained by the proposed and reference method revealed no significant difference in the performance of the two methods regarding the accuracy and precision respectively. The proposed method was further extended to the in-vitro and in-vivo determination of the drug in spiked and real human plasma. The mean percentage recoveries in spiked and real human plasma (n = 3) were 95.78 +/- 1.37 and 90.93 +/- 2.34 respectively. Interference arising from co-administered drugs was also studied. A proposal for the reaction pathway with o-phthalaldehyde was postulated.

Simultaneous determination of loratadine and desloratadine in pharmaceutical preparations using liquid chromatography with a microemulsion as eluent.

A rapid HPLC procedure for analytical quality control of pharmaceutical preparations containing the antihistaminic drug substance loratadine and/or its analog desloratadine (which is also an active metabolite of loratadine) was developed using a microemulsion as the eluent. The separation was performed on a column packed with cyanopropyl bonded stationary phase adopting UV detection at 247 nm using a flow rate of 1 ml/min. The optimized microemulsion mobile phase consisted of 0.1M sodium dodecyl sulphate, 1% octanol, 10% n-propanol and 0.3% triethylamine in 0.02 M phosphoric acid, pH 3.0. The developed method was validated in terms of specificity, linearity, lower limit of quantification, lower limit of detection, precision and accuracy. With the proposed method satisfactory resolution between loratadine and desloratadine (resolution factor=3.85). The method requires a minimum of sample handling and is rapid (10 min), and reproducible (R.S.D.<2.0%). The mean recoveries of the analytes in pharmaceutical preparations were in agreement with those obtained from a reference method, as revealed by statistical analysis of the obtained results using the Student's t-test and the variance ratio F-test. Pseudoephedrine, the co-formulated drug substance, did not interference with the assay and was successfully separated using the developed HPLC method.

Spectrophotometric determination of propranolol in formulations via oxidative coupling with 3-methylbenzothiazoline-2-one hydrazone.

A simple spectrophotometric method has been developed for the determination of propranolol hydrochloride in pure as well as in dosage forms. The method is based on the oxidative coupling reaction with 3-methylbenzothiazoline-2-one hydrazone. A mixture of an acidic solution of the chromogenic agent and the drug upon treatment with ceric ammonium sulfate produces an orange color peaking at 496 nm. The absorbance-calibration plot was linear over the range 1-10 microg/ml with minimum detectability (S/N=2) of 0.1 microg/ml (3.38x10(-7) M). The molar absorbitivity was 3.195x10(3) l/M/cm with correlation coefficient (n=10) of 0.9999. The different experimental parameters affecting the development and stability of the color were carefully studied and optimized. The proposed method was applied successfully to the determination of propranolol in its dosage forms. A proposal of the reaction pathway was presented.